GLP-1
Adocia today announced that five abstracts featuring applications of its BioChaperone® platform technology have been accepted for presentation at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) being held October 1-5, 2018 in Berlin, Germany.
Earlier this month, Novo Nordisk announced it was laying off 400 staffers in Denmark and China. Today, Reuters reports that the Danish company plans to lay off about 250 people in the United States.
Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.
Poietis and Prometheus, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.
Galapagos NV announced today the closing of its underwritten public offering of 2,961,373 American Depositary Shares (“ADSs”) at a price of $116.50 per ADS
Galapagos NV announces a share capital increase as a result of a public offering of American Depositary Shares.
Galapagos NV and MorphoSys AG announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.
Galapagos NV announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares (“ADSs”) at $116.50 per ADS, before underwriting discounts.
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
PRESS RELEASES